PARP drug for breast cancer with PALB2 inherited mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests a PARP-inhibitor medicine in people with advanced breast cancer who carry an inherited PALB2 gene change. It may help slow or shrink metastatic (spread) cancer after standard treatments have been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (over 18).
- You have an inherited PALB2 gene mutation in your germline (family) test, and you do not have a BRCA1 or BRCA2 mutation.
- Your breast cancer has spread (metastatic).
- Your cancer is either triple-negative, or HR-positive and HER2-negative (and has progressed after the required prior treatments).
- You’ve had prior treatment with both an anthracycline and a taxane, and you may have had platinum before under specific conditions.
- You’re not in “visceral crisis,” and your blood counts, liver, and kidney tests are strong enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug olaparib can help people with advanced pancreatic cancer that has a specific change in the PALB2 gene. You may qualify if your cancer has spread or cannot be removed with surgery and you have already tried at least one other treatment.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This trial tests if niraparib, a targeted therapy pill, can shrink advanced solid cancers that have specific DNA repair flaws (HRD). It's for people whose tumors have certain gene mutations or DNA damage signatures.
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
This Phase 1 study tests a combination of medicines (including niraparib and irinotecan) for advanced solid tumors that have specific DNA repair gene changes, such as BRCA1/2 or related defects. It aims to see whether the treatment can shrink tumors and is safe enough to continue studying.
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Hear when a new Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.